PIK3CA and follicular lymphoma: Duvelisib is an oral dual PI3Kγ and PI3Kδ inhibitor with IC50 values of 27 and 2.5 nM, respectively.391 It prevents the activation of PI3K-γ and δ isoforms by competitively and reversibly binding to the ATP-binding pocket of the p110 subunit.392 The FDA has approved duvelisib for the treatment of adult patients with relapsed or refractory CLL, SLL, and follicular lymphoma after at least two prior therapies.